Roger J. Pomerantz
Dr. Roger Pomerantz was named global head of infectious diseases at Merck & Co. in February 2010. Prior to that, Dr. Pomerantz served as president of Tibotec Pharmaceuticals Ltd., the Virology and Infectious Diseases Research and Development Company within Johnson & Johnson. Under his leadership, the company launched eight new drugs to treat HIV, HCV, and Multi-Drug Resistant Tuberculosis.
Dr. Pomerantz received his BS in biochemistry at the Johns Hopkins University and his MD at the Johns Hopkins School of Medicine. He completed his training at the Harvard Medical School and served as the chief medical resident. His post-doctoral research training in Molecular Retrovirology was obtained at Harvard and the Whitehead Institute for Biomedical Research at MIT in the laboratory of Nobel Laureate Dr. David Baltimore. Dr. Pomerantz is board certified in both Internal Medicine and Infectious Diseases. He was an endowed, tenured professor of Medicine, Biochemistry and Molecular Pharmacology, chief of Infectious Diseases, and the founding director and chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School.
Dr. Pomerantz has served as chairman of the Antiviral Advisory Panel for the U.S. Food and Drug Administration, and on numerous invited NIH advisory commissions, panels and committees. His awards and honors have included election as a Fellow to the American Association of Physicians, the American Society of Clinical Investigation, the American College of Physicians, the Infectious Diseases Society of America, and receiving the President’s Award of the International Society of Neurovirology.
